BUSINESS

Eisai’s Sleep Inducer Dayvigo Approved in Hong Kong

March 3, 2021

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Eisai said on March 2 that its sleep inducer Dayvigo (lemborexant) has been approved in Hong Kong, making it the first Asian market to give the green light to the drug outside Japan. Dayvigo was approved for the treatment of…

To read the full story

Eisai’s Sleep Inducer Dayvigo Now Available in Hong Kong
July 1, 2021
Eisai’s Sleep Inducer Dayvigo Accepted in Hong Kong
July 9, 2020

BUSINESS

Eisai Eyes 1 Trillion yen in FY2028 Sales under 3-Year Plan
May 26, 2026
Nippon Kayaku to Take Over AstraZeneca’s Zoladex in Japan
May 26, 2026
Jardiance Triumphs in Six Promotion Channels in April: Intage
May 26, 2026
NTT Data, Kindai Hospital Validate RWD-Based Patient Screening Technology
May 26, 2026
Enhertu Earns EMA Panel OK for HER2 Positive Solid Tumors
May 25, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Are Technical Discussions Enough for Japan’s CEA System?

By Ken Yoshino

Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…